Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00199875 · ClinicalTrials.gov registry record · Phase 1
Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250
A Phase 1 study, sponsored by Ludwig Institute for Cancer Research.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00199875 is a Phase 1 study that has completed, run by Ludwig Institute for Cancer Research. The registered enrollment target is 18 participants.
The verdict
NCT00199875, a Phase 1 study, has completed, sponsored by Ludwig Institute for Cancer Research.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This was a Phase 1, open-label, dose-escalation study of yttrium-90 conjugated chimeric G250 (\^90Y-DOTA-cG250) in patients with advanced, measurable clear cell renal cell carcinoma (RCC). Study objectives were to determine the safety, targeting, and dosimetry of \^90Y-DOTA-cG250, using indium-111 conjugated chimeric G250 (\^111In-DOTA-cG250) as a surrogate, as well as to evaluate the immunogenicity of cG250.
Interventions
- DRUG Yttrium-90 conjugated chimeric G250 (^90Y-DOTA-cG250)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2005-07-06 |
| Est. Completion | 2013-03-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00199875
The ClinicalTrials.gov registry entry for NCT00199875 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ludwig Institute for Cancer Research, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Yttrium-90 conjugated chimeric G250 (^90Y-DOTA-cG250) is the first listed.
NCT00199875 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00199875 about?
NCT00199875 is a clinical study titled "Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250". This was a Phase 1, open-label, dose-escalation study of yttrium-90 conjugated chimeric G250 (\^90Y-DOTA-cG250) in patients with advanced, measurable clear cell renal cell carcinoma (RCC). Study objectives were to determine the safety, targeting, and dosimetry of \^90Y-DOTA-cG250, using indium-111 c...
What is the current status of trial NCT00199875?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2005-07-06. Estimated completion is 2013-03-14.
What interventions are being tested in trial NCT00199875?
The interventions under investigation include: Yttrium-90 conjugated chimeric G250 (^90Y-DOTA-cG250) (DRUG).
Who is sponsoring clinical trial NCT00199875?
This trial is sponsored by Ludwig Institute for Cancer Research, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.